Attapon Cheepsattayakorn^1,3*, Ruangrong Cheepsattayakorn² and Porntep Siriwanarangsun³

¹10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
²Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
³Faculty of Medicine, Western University, Pathumtani Province, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: April 25, 2022; Published: April 29, 2022

Abstract

A recent study in South Africa demonstrated that IgG seroprevalence of SARS-CoV-2 (COVID-19) ranged from 56.2% (95% confidential interval (CI), 52.6 to 59.7) among children with age younger than 12 years to 79.7% (95% CI, 77.6 to 81.5) among adults with age older than 50 years [1]. Female patients were higher IgG-seroprevalence levels than male cases [1]. The Omicron variant was predominant during the latest COVID-19-pandemic fourth wave in this country with one month from the onset to the peak of this latest wave, compared to the previous third wave of the COVID-19 pandemic, whereas the incidences of hospital admission, excess death attributable to COVID-19 in this latest fourth wave were consistently lower than the earlier waves’ incidences [1]. In Omicron variant that mainly affecting spike protein, cell-mediated immunity is likely to be more durable than neutralizing-antibody-mediated immunity in the small mutation context [2], whereas natural infection induces cell-mediated immunity targeting membrane protein, nucleocapsid protein, and spike protein [3] and long-lived cytotoxic (CD8+) T cells with a half-life of 125 to 255 days [4].

References

1. Madhi SA., et al. “Population Immunity and Covid-19 Severity with Omicron Variant in South Africa”. The New England Journal of Medicine 386 (2022): 1314-1326.
2. Alter G., et al. “Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans”. Nature 596 (2021): 268-272.
3. Milne G., et al. “Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity ?” Lancet Respiratory Medicine 9 (2021): 1450-1466.
4. Dan IM., et al. “Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection”. Science 371 (2021): eabf45063.

Citation

Citation: Attapon Cheepsattayakorn., et al. “COVID-19 Severity with Omicron Variant Infection". Acta Scientific Microbiology 5.5 (2022): 01.

Copyright

Copyright: © 2022 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.